Skip to main content
Explore URMC
menu

Lymphoma (iNHL): A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma (ILyAD)

Research Question:
Can modification of vitamin D levels in the blood, through supplementation, improve outcomes in patients with indolent lymphoma treated with rituximab?

Basic Study Information

Purpose:
If you decide and are eligible to take part in this study, in addition to the standard treatment, rituximab, you will be randomized to receive an oral dose of either 2,000 IU vitamin D (also called cholecalciferol) supplementation or placebo. The randomization will be 2:1. A 2:1 randomization means for every three people enrolled on the study, two people will receive vitamin D and one person will receive placebo. This study is conducted in a double blind fashion, which means neither you nor your doctor will know which treatment group you are in.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03078855?term=ilyad&rank=1
Study Reference #: ULYM17025

Lead Researcher (Principal Investigator)

Lead Researcher:  Jonathan Friedberg, MD

Study Contact Information

Study Coordinator: Par Ranjbar
Phone: (585) 275-3817
Email: Parastou_Azadehranjbar@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoma

Return to Search